Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model

Blood

Volumn 96, Issue 6, 2000, Pages 2108-2115

  Rhoades, K L ^a   Hetherington, C J ^a   Harakawa, N ^a   Yergeau, D A ^a   Zhou, L ^a   Liu, L Q ^a   Little, M T ^a   Tenen, D G ^a   Zhang, D E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; TETRACYCLINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AML1 ETO; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; FEMALE; HEMATOPOIETIC CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034665765     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.6.2108.h8002108_2108_2115     Document Type: Article

References (39)

1. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
2. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
3. Transcription factors, normal myeloid development, and leukemia
4. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor
5. The Runt domain identifies a new family of heteromeric transcriptional regulators
6. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia
7. t(8;21) Breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1
8. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis
9. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
10. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt
11. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells
12. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
13. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis
14. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta
15. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor
16. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
17. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
18. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter
19. Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene
20. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice
21. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions
22. Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system
23. Characterization of human endotoxin lipopolysaccharide receptor CD14 expression in transgenic mice
24. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: Implications for t(8;21) leukemogenesis and monitoring residual disease
25. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL
26. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AM1-ETO-expressing mice, functions in hematopoietic cell differentiation
27. Recurring chromosome abnormalities in leukemia and lymphoma
28. Seed versus soil: The importance of the target cell for transgenic models of human leukemias
29. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences
30. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice
31. A PML-RARalpha transgene initiates murine acute promyelocytic leukemia
32. Transgenic expression of PML/RARalpha impairs myelopoiesis
33. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia
34. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay
35. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21)
36. Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
37. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
38. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
39. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia